Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), informs its shareholders that the Annual General Meeting will be held on 12 June 2024 at 2.00pm at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.
The notice for the meeting, including the agenda of the day as well as the motions put to the vote, has been published on May 23 in the Feuille Officielle Suisse du Commerce.
The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: www.geneuro.com, under the section Investors Documentation Shareholders meeting.
It is also possible to consult the documents at the Company's headquarters, chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates. Each shareholder has the right to request a hard copy of those documents.
About GeNeuro
GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529578089/en/
Contacts:
GeNeuro's contacts:
GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com
NewCap (France)
Mathilde Bohin Louis-Victor Delouvrier (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 94 98
geneuro@newcap.eu
